Journal of Crohn's & colitis | 30 Sep 2016
S Vermeire, EV Loftus, JF Colombel, BG Feagan, WJ Sandborn, BE Sands, S Danese, GR D'Haens, A Kaser, R Panaccione, DT Rubin, I Shafran, M McAuliffe, A Kaviya, S Sankoh, R Mody, B Abhyankar and M Smyth
Vedolizumab is a gut-selective α4β7 integrin antagonist therapy for ulcerative colitis and Crohn’s disease. The GEMINI long-term safety (LTS) trial is an ongoing open-label study investigating the safety of vedolizumab. We present interim exploratory analyses of efficacy in patients with Crohn’s disease.
* Data courtesy of Altmetric.com